cinromide

Known as: 3-(3-bromophenyl)-N-ethyl-2-propenamide, 3-bromo-N-ethylcinnamide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1979-1988
024619791988

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
  • Epilepsia
  • 1989
This study evaluated the effects of cinromide in patients with Lennox-Gastaut Syndrome. No difference between cinromide and… (More)
Is this relevant?
1985
1985
A previous study of the metabolic fate of cinromide (3-bromo-N-ethylcinnamamide) in rhesus monkey established that half of a dose… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1983
1983
Monotherapy with the experimental antiepileptic drug cinromide was evaluated in 11 adult outpatients with uncontrolled partial… (More)
Is this relevant?
1983
1983
A double-blind controlled trial of cinromide in 25 adult subjects with refractory epilepsy using the maximum tolerated dose… (More)
Is this relevant?
1983
1983
Fifty percent of a cinromide dose was metabolized to an active metabolite in the rhesus monkey. The steady-state concentration of… (More)
Is this relevant?
1983
1983
The dose-dependent nonlinearity of the clearance of cinromide, a medium extraction ratio drug, has been established in two… (More)
Is this relevant?
1983
1983
Cinromide (BW-122U) was evaluated in an open pilot study of absence seizures in three naive (previously untreated for absence… (More)
Is this relevant?
1981
1981
Cinromide is an experimental anticonvulsant currently in phase II testing. A single oral dose (900 mg) of cinromide was… (More)
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
1980
1980
A quantitative thin-layer chromatography (TLC) procedure is described for the analysis of cinromide (3-bromo-N-ethylcinnamamide… (More)
Is this relevant?
1979
1979
Cinromide (3 brono-N-ethylcinnamide), an experimental anticonvulsant (Burroughs-Wellcome Pharmaceutical Co.), was given a… (More)
Is this relevant?